SI3153171T1 - Samidorfan (ALKS 33) v kombinaciji z buprenorfinom za zdravljenje depresivnih motenj - Google Patents

Samidorfan (ALKS 33) v kombinaciji z buprenorfinom za zdravljenje depresivnih motenj

Info

Publication number: SI3153171T1
Authority: SI; Slovenia
Prior art keywords: samidorphan; alks; buprenorphine; treatment; combination
Prior art date: 2011-12-15

Application number

SI201231474T

Other languages

English (en)

Inventor

Daniel Deaver

Elliott Ehrich

Original Assignee

Alkermes Pharma Ireland Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-15

Filing date

2012-12-14

Publication date

2019-01-31

2012-12-14 Application filed by Alkermes Pharma Ireland Limited filed Critical Alkermes Pharma Ireland Limited

2019-01-31 Publication of SI3153171T1 publication Critical patent/SI3153171T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SI201231474T 2011-12-15 2012-12-14 Samidorfan (ALKS 33) v kombinaciji z buprenorfinom za zdravljenje depresivnih motenj SI3153171T1 (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161576233P	2011-12-15	2011-12-15
EP16201359.3A EP3153171B1 (en)	2011-12-15	2012-12-14	Samidorphan (alks 33) in combination with buprenorphine for the treatment of depressive disorders

Publications (1)

Publication Number	Publication Date
SI3153171T1 true SI3153171T1 (sl)	2019-01-31

Family

ID=47757653

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201231474T SI3153171T1 (sl)	2011-12-15	2012-12-14	Samidorfan (ALKS 33) v kombinaciji z buprenorfinom za zdravljenje depresivnih motenj

Country Status (25)

Country	Link
US (8)	US8822488B2 (sl)
EP (3)	EP3415148A1 (sl)
JP (2)	JP6038170B2 (sl)
KR (1)	KR101996108B1 (sl)
CN (2)	CN104159586A (sl)
AU (1)	AU2012351806C1 (sl)
BR (1)	BR112014012409B8 (sl)
CA (1)	CA2858812C (sl)
CY (1)	CY1121081T1 (sl)
DK (1)	DK3153171T3 (sl)
EA (1)	EA030609B8 (sl)
ES (2)	ES2692771T3 (sl)
HR (1)	HRP20181950T1 (sl)
HU (1)	HUE041883T2 (sl)
IL (1)	IL232785B (sl)
LT (1)	LT3153171T (sl)
MX (1)	MX375348B (sl)
PL (1)	PL3153171T3 (sl)
PT (1)	PT3153171T (sl)
RS (1)	RS58322B1 (sl)
SI (1)	SI3153171T1 (sl)
SM (1)	SMT201800664T1 (sl)
TR (1)	TR201815154T4 (sl)
WO (1)	WO2013088243A1 (sl)
ZA (1)	ZA201405029B (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE043963T2 (hu)	2009-12-04	2019-09-30	Alkermes Pharma Ireland Ltd	Morfinán származékok gyógyszer-túladagolás kezelésére
PT3446565T (pt)	2010-08-23	2024-01-29	Alkermes Pharma Ireland Ltd	Métodos para tratar o aumento de peso induzido por antipsicóticos
US9211293B2 (en)	2011-12-15	2015-12-15	Alkermes Pharma Ireland Limited	Opioid agonist antagonist combinations
CA2858812C (en)	2011-12-15	2019-02-26	Alkermes Pharma Ireland Limited	Compositions of buprenorphine and mu-opioid receptor antagonists
US9656961B2 (en)	2013-05-24	2017-05-23	Alkermes Pharma Ireland Limited	Methods for treating depressive symptoms
WO2014190270A1 (en)	2013-05-24	2014-11-27	Alkermes Pharma Ireland Limited	Morphan and morphinan analogues, and methods of use
TWI768557B (zh)	2015-02-02	2022-06-21	美商佛瑪治療公司	作為ｈｄａｃ抑制劑之3-烷基-4-醯胺基-雙環[4,5,0]羥肟酸
WO2016126726A1 (en)	2015-02-02	2016-08-11	Forma Therapeutics, Inc.	Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
US10555935B2 (en)	2016-06-17	2020-02-11	Forma Therapeutics, Inc.	2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
WO2022101444A1 (en)	2020-11-12	2022-05-19	Alkermes Pharma Ireland Limited	Immediate release multilayer tablet

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH581624A5 (sl)	1970-08-14	1976-11-15	Sumitomo Chemical Co
US3856795A (en)	1972-04-25	1974-12-24	American Home Prod	Process for preparation of secondary amines from tertiary amines
US4032529A (en)	1974-09-20	1977-06-28	Sterling Drug Inc.	Aminomethanobenzazocine intermediates
US3957793A (en)	1974-09-20	1976-05-18	Sterling Drug Inc.	Hydroxyiminobenzazocines
US4127577A (en)	1975-11-24	1978-11-28	Sterling Drug Inc.	Aminomethanobenzazocine process
US4205171A (en)	1976-01-12	1980-05-27	Sterling Drug Inc.	Aminomethanobenzazocines and nitromethanobenzazocines
US4464378A (en)	1981-04-28	1984-08-07	University Of Kentucky Research Foundation	Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8332556D0 (en) *	1983-12-06	1984-01-11	Reckitt & Colmann Prod Ltd	Analgesic compositions
US4649200A (en)	1986-05-08	1987-03-10	Regents Of The University Of Minnesota	Substituted pyrroles with opioid receptor activity
US4939264A (en)	1986-07-14	1990-07-03	Abbott Laboratories	Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en)	1991-06-05	1993-11-02	The United States Of America As Represented By The Secretary Of The Army	(+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en)	1992-06-26	1997-03-04	Boehringer Ingelheim Kg	Useful for treating neurodegenerative diseases
SE9103745D0 (sv)	1991-12-18	1991-12-18	Wikstroem Haakan	Aryl-triflates and related compounds
EP0632041A1 (en)	1993-07-01	1995-01-04	Katholieke Universiteit Nijmegen	New morphine derivatives having improved analgesic and narcotic properties
ATE229958T1 (de)	1996-01-10	2003-01-15	Glaxosmithkline Spa	Heterocyclische kondensierte morphin-derivate
GB9709972D0 (en)	1997-05-19	1997-07-09	Pfizer Ltd	Tetrazoles
US7534866B2 (en) *	2005-10-19	2009-05-19	Ibc Pharmaceuticals, Inc.	Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9912411D0 (en)	1999-05-28	1999-07-28	Pfizer Ltd	Compounds useful in therapy
AU2002227135B2 (en)	2000-10-31	2008-01-03	Rensselaer Polytechnic Institute	8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
WO2003079945A1 (en) *	2002-03-20	2003-10-02	Euro-Celtique S.A.	Method of administering buprenorphine to treat depression
AU2003239389A1 (en)	2002-05-30	2003-12-19	Eli Lilly And Company	Opioid receptor antagonists
AU2005245403B2 (en)	2004-05-14	2012-04-19	Janssen Pharmaceutica N.V.	Carboxamido opioid compounds
US20060063792A1 (en) *	2004-09-17	2006-03-23	Adolor Corporation	Substituted morphinans and methods of their use
WO2006052710A1 (en)	2004-11-05	2006-05-18	Rensselaer Polytechnic Institute	4-hydroxybenzomorphans
ES2440590T3 (es)	2005-03-02	2014-01-29	Takeda Gmbh	Nuevas sales de derivados de hexahidrofenantridina 6-heterociclil-sustituidos
EP2134330B1 (en)	2007-03-19	2013-05-08	Acadia Pharmaceuticals Inc.	Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
ES2586245T3 (es)	2007-08-09	2016-10-13	Rensselaer Polytechnic Institute	Carboxamidas cuaternarias opioides
WO2009103004A1 (en) *	2008-02-14	2009-08-20	Alkermes, Inc.	Selective opioid compounds
WO2009126931A2 (en) *	2008-04-11	2009-10-15	Xvasive, Inc.	Combination therapy for bipolar disorder
EP2408303A4 (en) *	2009-03-19	2012-07-25	Alkermes Inc	MORPHINANE DERIVATIVES HAVING HIGH ORAL BIOLOGICAL AVAILABILITY
US20120149724A1 (en)	2009-06-04	2012-06-14	The General Hospital Corporation	Modulating endogenous beta-endorphin levels
US8530479B2 (en) *	2009-08-10	2013-09-10	Daljit Singh Dhanoa	Deuterium-enriched alkyl sulfonamides
HUE043963T2 (hu) *	2009-12-04	2019-09-30	Alkermes Pharma Ireland Ltd	Morfinán származékok gyógyszer-túladagolás kezelésére
US9211293B2 (en) *	2011-12-15	2015-12-15	Alkermes Pharma Ireland Limited	Opioid agonist antagonist combinations
CA2858812C (en)	2011-12-15	2019-02-26	Alkermes Pharma Ireland Limited	Compositions of buprenorphine and mu-opioid receptor antagonists
US9656961B2 (en) *	2013-05-24	2017-05-23	Alkermes Pharma Ireland Limited	Methods for treating depressive symptoms

2012
- 2012-12-14 CA CA2858812A patent/CA2858812C/en active Active
- 2012-12-14 SM SM20180664T patent/SMT201800664T1/it unknown
- 2012-12-14 WO PCT/IB2012/002900 patent/WO2013088243A1/en active Application Filing
- 2012-12-14 EP EP18187096.5A patent/EP3415148A1/en not_active Withdrawn
- 2012-12-14 HU HUE16201359A patent/HUE041883T2/hu unknown
- 2012-12-14 ES ES16201359.3T patent/ES2692771T3/es active Active
- 2012-12-14 AU AU2012351806A patent/AU2012351806C1/en not_active Ceased
- 2012-12-14 DK DK16201359.3T patent/DK3153171T3/en active
- 2012-12-14 EA EA201491153A patent/EA030609B8/ru unknown
- 2012-12-14 EP EP12830900.2A patent/EP2790702B1/en active Active
- 2012-12-14 PT PT16201359T patent/PT3153171T/pt unknown
- 2012-12-14 MX MX2014007042A patent/MX375348B/es active IP Right Grant
- 2012-12-14 KR KR1020147016224A patent/KR101996108B1/ko not_active Expired - Fee Related
- 2012-12-14 PL PL16201359T patent/PL3153171T3/pl unknown
- 2012-12-14 EP EP16201359.3A patent/EP3153171B1/en active Active
- 2012-12-14 JP JP2014546667A patent/JP6038170B2/ja not_active Expired - Fee Related
- 2012-12-14 US US13/715,198 patent/US8822488B2/en active Active
- 2012-12-14 ES ES12830900T patent/ES2791764T3/es active Active
- 2012-12-14 CN CN201280062291.6A patent/CN104159586A/zh active Pending
- 2012-12-14 RS RS20181543A patent/RS58322B1/sr unknown
- 2012-12-14 BR BR112014012409A patent/BR112014012409B8/pt not_active IP Right Cessation
- 2012-12-14 SI SI201231474T patent/SI3153171T1/sl unknown
- 2012-12-14 CN CN201611052441.1A patent/CN106727562B/zh not_active Expired - Fee Related
- 2012-12-14 LT LTEP16201359.3T patent/LT3153171T/lt unknown
- 2012-12-14 TR TR2018/15154T patent/TR201815154T4/tr unknown
2014
- 2014-05-25 IL IL232785A patent/IL232785B/en active IP Right Grant
- 2014-07-10 ZA ZA2014/05029A patent/ZA201405029B/en unknown
- 2014-07-29 US US14/445,407 patent/US9498474B2/en active Active
2016
- 2016-03-10 US US15/066,567 patent/US9918978B2/en active Active
- 2016-07-29 JP JP2016150353A patent/JP6403726B2/ja not_active Expired - Fee Related
- 2016-09-12 US US15/262,628 patent/US9913837B2/en active Active
2017
- 2017-09-28 US US15/718,139 patent/US10314838B2/en active Active
- 2017-10-02 US US15/722,408 patent/US10188643B2/en active Active
2018
- 2018-11-22 HR HRP20181950TT patent/HRP20181950T1/hr unknown
- 2018-12-18 CY CY181101356T patent/CY1121081T1/el unknown
2019
- 2019-04-25 US US16/394,524 patent/US10806731B2/en active Active
2020
- 2020-10-06 US US17/063,892 patent/US20210196703A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL3153171T3 (pl)	2019-02-28
US20190247387A1 (en)	2019-08-15
US9913837B2 (en)	2018-03-13
IL232785A0 (en)	2014-07-31
BR112014012409B1 (pt)	2022-08-23
AU2012351806C1 (en)	2016-06-16
EA030609B8 (ru)	2018-10-31
CA2858812A1 (en)	2013-06-20
US20180078543A1 (en)	2018-03-22
ZA201405029B (en)	2015-10-28
MX2014007042A (es)	2015-01-22
NZ624056A (en)	2016-07-29
US8822488B2 (en)	2014-09-02
JP6038170B2 (ja)	2016-12-07
ES2692771T3 (es)	2018-12-05
KR101996108B1 (ko)	2019-10-01
MX375348B (es)	2025-03-06
US9918978B2 (en)	2018-03-20
CN104159586A (zh)	2014-11-19
CN106727562B (zh)	2019-07-05
US20150051240A1 (en)	2015-02-19
US20130190342A1 (en)	2013-07-25
BR112014012409A2 (pt)	2017-06-13
CN106727562A (zh)	2017-05-31
JP2016222706A (ja)	2016-12-28
US10188643B2 (en)	2019-01-29
RS58322B1 (sr)	2019-03-29
KR20140107258A (ko)	2014-09-04
DK3153171T3 (en)	2018-11-19
WO2013088243A1 (en)	2013-06-20
US20170056392A1 (en)	2017-03-02
EP2790702B1 (en)	2020-04-01
US20160256450A1 (en)	2016-09-08
EA030609B1 (ru)	2018-08-31
LT3153171T (lt)	2018-12-10
AU2012351806B2 (en)	2016-03-10
JP2015505853A (ja)	2015-02-26
EP3153171A1 (en)	2017-04-12
US20180078542A1 (en)	2018-03-22
US10806731B2 (en)	2020-10-20
EP2790702A1 (en)	2014-10-22
HRP20181950T1 (hr)	2019-03-22
CA2858812C (en)	2019-02-26
BR112014012409B8 (pt)	2022-09-13
TR201815154T4 (tr)	2018-11-21
SMT201800664T1 (it)	2019-01-11
ES2791764T3 (es)	2020-11-05
US20210196703A1 (en)	2021-07-01
EP3153171B1 (en)	2018-09-19
EP3415148A1 (en)	2018-12-19
EA201491153A1 (ru)	2015-04-30
US9498474B2 (en)	2016-11-22
IL232785B (en)	2021-04-29
PT3153171T (pt)	2018-11-16
HUE041883T2 (hu)	2019-06-28
US10314838B2 (en)	2019-06-11
JP6403726B2 (ja)	2018-10-10
CY1121081T1 (el)	2019-12-11
AU2012351806A1 (en)	2014-05-15

Publication	Publication Date	Title
HRP20181950T1 (hr)	2019-03-22	Samidorfan (alks 33) u kombinaciji s buprenorfinom za liječenje depresivnih poremećaja
IL260585B (en)	2019-08-29	Preparations and methods for the treatment of diseases related to the retina of the eye
EP2552433A4 (en)	2013-11-06	COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
IL226401A0 (en)	2013-07-31	Methods for treating disorders related to @fgfBA
GB201115711D0 (en)	2011-10-26	Phyto-cannabinoids for use in the treatment of cancer
ZA201304334B (en)	2014-12-23	Methods for diagnosing and treating eye-length related disorders
IL228030A0 (en)	2013-09-30	Methods and compositions for the treatment of gout and gout-related metabolic disorders
HK1194665A1 (zh)	2014-10-24	用於治療神經系統病症的組合物
EP2696874A4 (en)	2015-06-10	COMPOSITIONS AND METHODS USED TO TREAT NASAL CONDITIONS
ZA201304822B (en)	2014-03-26	Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
SG2014014724A (en)	2014-07-30	METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
HK1192726A1 (en)	2014-08-29	1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
IL231593B (en)	2019-01-31	Buprenorphine for the treatment of acute suicidality
EP2709632A4 (en)	2015-03-04	COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
EP2681209A4 (en)	2014-12-10	COMPOUNDS AND METHODS FOR TREATING PAIN AND OTHER DISEASES
ZA201408060B (en)	2016-03-30	Compositions and methods for the treatment of neurological disorders
HK1186986A1 (zh)	2014-03-28	治療皮膚病的方法
ZA201408061B (en)	2016-04-28	Compositions and methods for the treatment of neurological disorders
ZA201408058B (en)	2016-03-30	Compositions and methods for the treatment of epilepsy
PH12014501052A1 (en)	2014-06-30	Methods and compositions for the treatment of diabetes and related symptoms
GB201009037D0 (en)	2010-07-14	Compositions and methods for treating disorders associated with atherosclerotic plaques
GB201119458D0 (en)	2011-12-21	Compositions for treatment of sleep disorders
GB201107553D0 (en)	2011-06-22	Composition and methods for the treatment of neuroendocrine and pitutitary tumoars
GB201106142D0 (en)	2011-05-25	Compounds for the treatment of metabolic disorders
GB201106154D0 (en)	2011-05-25	Compounds for the treatment of metabolic disorders